Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in TexasPRNewsWire • 09/23/25
Mounjaro, Ozempic: Obesity market shifting to portfolio play as GLP-1 innovation peaks, says leading bankProactive Investors • 09/23/25
Boys & Girls Clubs of America Receives $10 Million Grant from Lilly Endowment Inc. to Help Transform the Future of Youth Programs in and Around Native CommunitiesGlobeNewsWire • 09/23/25
These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big TechMarket Watch • 09/22/25
Eli Lilly: Orforglipron Sets Path Of Continued Revenue Growth In T2D And ObesitySeeking Alpha • 09/21/25
2 Magnificent S&P 500 Dividend Stocks Down 7% and 19% to Buy and Hold ForeverThe Motley Fool • 09/20/25
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?Zacks Investment Research • 09/18/25
Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy TodayThe Motley Fool • 09/18/25
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFsBenzinga • 09/18/25
No more need for needles: A new generation of GLP-1 weight-loss drugs in pill form is coming closerWSJ • 09/18/25
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: StudyBenzinga • 09/18/25
Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.Barrons • 09/18/25
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetesPRNewsWire • 09/17/25
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?Zacks Investment Research • 09/17/25
Data on Eli Lilly's Weight Loss Pill Hasn't Thrilled Investors. New Updates Are Complicating the Picture.Barrons • 09/17/25